GlassScriptPhysician profile
Toran J Macarthur
NPI 1063521177
$10,113.57
in general payments reported to CMS, 2019-2025
71 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,172 · 2021: $1,983 · 2022: $1,376 · 2023: $1,352 · 2024: $1,661 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.21 |
| Education | $145.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,730.54 | 2019-2025 | |
| Astellas Pharma US INC | $807.58 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $779.24 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $502.47 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $404.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.19 | 2019-2025 | Jardiance |
| Amgen INC. | $302.30 | 2020-2025 | Repatha, Otezla, Evenity |
| Tris Pharma INC | $288.31 | 2019-2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $274.51 | 2019-2023 | |
| Novo Nordisk INC | $260.95 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $257.49 | 2019-2024 | Xarelto |
| Supernus Pharmaceuticals, INC. | $236.56 | 2020-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $228.47 | 2019-2024 | Jornay Pm |
| Antares Pharma, INC. | $198.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $188.24 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toran Macarthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.